chemotherapy
PredicTx expands clinical trial from Australia to India and the Middle East while working towards TGA approval and CE marking.
The oncology-focused company will use the funds to boost manufacturing capacity, grow its commercial team and develop its next-generation Amma product.
The company will use the funds to support a 510(k) submission to the FDA for its Flexi-Port SLF-TANL for oncology patients.